

PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:

OKABE, Masao  
No.602, Fuji Bldg., 2-3  
, Marunouchi  
3-chome, Chiyoda-ku, Tokyo  
1000005  
Japan

PCT



WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing  
(day/month/year)

29. 3. 2005

FOR FURTHER ACTION

See paragraph 2 below

Applicant's or agent's file reference  
**10003825W001**

International application No.

**PCT/JP2004/19289**

International filing date (day/month/year)

**16.12.2004**

Priority date (day/month/year)

**16.12.2003**

International Patent Classification (IPC) or both national classification and IPC

Int.Cl<sup>7</sup> **C12M1/00, 3/00, C12Q1/02**

Applicant

**CANON KABUSHIKI KAISHA**

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Date of completion of this opinion

**14.03.2005**

Name and mailing address of the ISA/JP

**Japan Patent Office**

3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan

Authorized officer

**TANAKA Harue**

Telephone No. +81-3-3581-1101 Ext. 3488

**4N 9739**

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
**PCT/JP2004/19289**

**Box No. I Basis of the opinion**

1. With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

This opinion has been established on the basis of a translation from the original language into the following language \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).

2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

- a sequence listing  
 table(s) related to the sequence listing

b. format of material

- in written format  
 in computer readable form

c. time of filing/furnishing

- contained in the international application as filed.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority for the purposes of search.

3.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
**PCT/JP2004/ 19289**

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Claims <u>1-36</u>	YES
	Claims	_____
Inventive step (IS)	Claims <u>1-36</u>	YES
	Claims	_____
Industrial applicability (IA)	Claims <u>1-36</u>	YES
	Claims	_____

**2. Citations and explanations**

**The following documents have been considered for the purpose of this report:**

**D1=JP 2003-504011 A(Richard M.KRIS)2003.02.04  
& WO 99/32663 A2 & EP 1038033 A & US 6232066 B1**

**D2=JP 2000-508528 A(THE PERKIN-ELMER CORPORATION)2000.07.11  
& WO 97/36681 A1 & EP 889751 A & US 6124138 A1**

**D3=JP 2002-355025 A(CANON KK)2002.12.10  
& EP 1248108 A2 & US 2002/0177221 A1**

**D4=JP 2002-355026 A(CANON KK)2002.12.10  
& EP 12253196 A2 & US 2002/01827221 A1**

**The subject matters of claim 1-36 are neither disclosed in any of D1-D4 nor obvious to a person skilled in the art.**

**The subject matters of claim 1-36 are considered to involve an inventive step over D1-D4.**

**A cellular screening substratum or apparatus is described ,which is characterized in that plural cellular screening substances are positioned,in D1-D4 each.**

**But none of the prior art D1-D4 describes a transfer sheet that transfers a biologically active substance to a culture region on a culture plate when placed on the culture plate, and it was not obvious for the person skilled in the art to employ that the technical feature.**